Gopten (Trandolapril)

Gopten (trandolapril) is employed in several cardiovascular indications where reduction of blood pressure and cardiac workload is desired.

• Management of essential hypertension, often as first‑line therapy.
• Treatment of chronic heart failure to improve symptoms and reduce hospitalizations.
• Long‑term therapy after myocardial infarction to lower the risk of recurrent events.
• Adjunctive use in patients with diabetic kidney disease to slow progression of nephropathy.
• Supportive role in reducing the incidence of stroke in high‑risk hypertensive patients.
• Use in combination with diuretics or calcium channel blockers when monotherapy does not achieve target blood pressure.

Like other ACE inhibitors, trandolapril may cause a range of adverse effects that vary in frequency and severity.

Common

• Persistent dry cough that may worsen at night.
• Dizziness or light‑headedness, particularly upon standing quickly.
• Headache of mild to moderate intensity.
• Mild increase in blood potassium (hyperkalaemia) in patients with renal impairment.
• Fatigue or general weakness, especially during dose titration.
• Reduced exercise tolerance in some individuals.

Serious

• Angio‑edema involving the face, lips, tongue, or airway, which can be life‑threatening.
• Marked hypotension causing fainting or syncope, especially after the first dose.
• Acute kidney injury indicated by a rapid rise in serum creatinine.
• Significant elevation of liver enzymes suggesting hepatic injury.
• Severe allergic reaction presenting as rash, urticaria, or Stevens‑Johnson syndrome.
• Rapid heart rate (tachycardia) associated with severe hypotension.

When prescribing Gopten, clinicians should evaluate several precautionary factors to ensure safe use and minimize risks.

• Assess renal function before initiation and monitor periodically, as dose adjustment may be required.
• Check serum potassium levels, especially in patients receiving potassium‑sparing diuretics or supplements.
• Use caution in patients with a history of angio‑edema related to ACE inhibitors or ARBs.
• Avoid use during pregnancy; teratogenic risk is unknown but ACE inhibitors are contraindicated.
• Consider lower starting doses in elderly patients due to increased sensitivity to hypotension.
• Review concomitant use of NSAIDs, which can impair renal function and diminish antihypertensive effect.

Trandolapril may interact with other medicines, altering its effectiveness or increasing the risk of adverse events.

Avoid

• Concomitant use with other ACE inhibitors or ARBs, which can cause additive hypotension and hyperkalaemia.
• Use with aliskiren in patients with diabetes or renal impairment, due to increased risk of renal dysfunction.
• Simultaneous administration with potassium supplements or potassium‑sparing diuretics, which may lead to dangerous hyperkalaemia.

Use with caution

• Non‑steroidal anti‑inflammatory drugs (NSAIDs) may reduce antihypertensive effect and impair renal function; monitor kidney parameters.
• Diuretics, especially thiazides, can enhance the blood‑pressure‑lowering effect and cause volume depletion; adjust dose as needed.
• Lithium levels may increase, potentially causing toxicity; check serum lithium concentrations.